ClinicalTrials.gg
Not yet recruitingNCT07937813taVNS-VOICEUpdated Nov 16, 2026

Effects of Unilateral and Bilateral Transcutaneous Auricular Vagus Nerve Stimulation on Voice Acoustics in Healthy Adults

An interventional study of Unilateral Active taVNS and Bilateral Sham taVNS in Voice Quality, sponsored by Sinop University. Not yet recruiting. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Sinop University · Not applicable, Interventional, and Basic science

How we know

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Study summary

This study aims to investigate the immediate effects of transcutaneous auricular vagus nerve stimulation (taVNS) on voice characteristics and autonomic function in healthy adults.

A total of 36 healthy adults aged 18-30 years will participate in this randomized, sham-controlled, three-period crossover trial. Each participant will receive three interventions in a randomized order: unilateral active taVNS, bilateral active taVNS, and sham stimulation. Each intervention will last 20 minutes, with at least seven days between visits.

Voice characteristics will be evaluated before and after each intervention using acoustic analysis. The primary outcome will be shimmer, a measure of variation in voice amplitude. Secondary outcomes will include jitter, harmonics-to-noise ratio, and fundamental frequency. Perceived vocal effort, heart rate, and pulse rate variability will also be assessed.

The study will compare the immediate effects of unilateral, bilateral, and sham stimulation on voice stability and explore possible relationships between voice changes and autonomic responses.

Read the detailed description

This prospective, randomized, sham-controlled, three-period crossover trial will investigate the acute effects of unilateral and bilateral transcutaneous auricular vagus nerve stimulation (taVNS) on acoustic voice parameters and autonomic function in healthy adults.

Thirty-six participants aged 18-30 years will be allocated to one of six intervention sequences (ABC, ACB, BAC, BCA, CAB, or CBA). Each participant will complete three intervention visits separated by a washout period of at least seven days.

The intervention conditions will include: (A) unilateral active stimulation of the left cymba conchae, (B) bilateral active stimulation of the cymba conchae, and (C) bilateral sham stimulation applied to the earlobes with an initial brief sensory stimulation followed by gradual reduction of current to zero. Stimulation will be delivered using Nurosym devices at 20 Hz and 200 μs for 20 minutes. Active stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.

Acoustic voice assessment will involve three recordings of sustained /a/ phonation before and after each intervention. Recordings will be analyzed using Praat software. Shimmer (%) will be the primary outcome, while jitter (%), harmonics-to-noise ratio (dB), and fundamental frequency (Hz) will be secondary outcomes.

Perceived vocal effort will be assessed using a 100-mm visual analogue scale. Autonomic responses will be evaluated using pulse rate variability measurements obtained with the Polar Verity Sense device, including RMSSD, SDNN, and mean heart rate.

Primary analyses will use linear mixed-effects models to compare changes across intervention conditions while accounting for repeated measurements and study periods. Adverse events and stimulation tolerability will be monitored throughout the study.

02

Conditions studied

  • Voice Quality

Keywords

  • Transcutaneous Auricular Vagus Nerve Stimulation
  • taVNS
  • Acoustic Voice Analysis
  • Shimmer
  • Pulse Rate Variability
  • Crossover Trial
03

In context

Lead sponsor

Sinop University is the lead sponsor of 35 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-30 years.
  • Self-reported good general health without known systemic diseases preventing safe participation.
  • Native Turkish speakers.
  • No current hoarseness, vocal strain, or known laryngeal/voice disorders.
  • No current use of cigarettes, electronic cigarettes, heated tobacco, or other nicotine products.
  • Ability and willingness to attend three intervention visits separated by at least 7 days.
  • Ability to understand and follow study procedures.
  • Provision of written .

Exclusion criteria

Exclusion Criteria:

  • Known cardiovascular disease, arrhythmia, uncontrolled hypertension or hypotension, or unexplained syncope.
  • History of epilepsy, seizures, or serious neurological disorders.
  • Known vocal fold or laryngeal pathology, chronic voice disorders, previous laryngeal surgery, or significant hoarseness.
  • Active respiratory infection, laryngitis, sore throat, or febrile illness.
  • Ear infections, wounds, dermatological lesions, , or piercings interfering with electrode placement.
  • Pacemakers, implantable cardioverter-defibrillators, or other active electronic implants.
  • Pregnancy or suspected pregnancy.
  • Current tobacco or nicotine use.
  • Regular use of medications significantly affecting autonomic function or voice, including beta-blockers, antiarrhythmics, anticholinergics, sedatives, or psychoactive medications.
  • Failure to comply with pre-assessment restrictions concerning caffeine, alcohol, vigorous exercise, or vocal loading; visits may be rescheduled when possible.
  • Clinically significant intolerance or adverse reactions to stimulation requiring discontinuation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Sequence ABC

    Unilateral active taVNS, followed by bilateral active taVNS, then bilateral sham stimulation. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

    Device: Unilateral Active taVNS · Device: Bilateral Sham taVNS

  • Experimental
    Sequence ACB

    Unilateral active taVNS, followed by bilateral sham stimulation, then bilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

    Device: Unilateral Active taVNS · Device: Bilateral Sham taVNS

  • Experimental
    Sequence BAC

    Bilateral active taVNS, followed by unilateral active taVNS, then bilateral sham stimulation. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

    Device: Unilateral Active taVNS · Device: Bilateral Sham taVNS

  • Experimental
    Sequence BCA

    Bilateral active taVNS, followed by bilateral sham stimulation, then unilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

    Device: Unilateral Active taVNS · Device: Bilateral Sham taVNS

  • Experimental
    Sequence CAB

    Bilateral sham stimulation, followed by unilateral active taVNS, then bilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

    Device: Unilateral Active taVNS · Device: Bilateral Sham taVNS

  • Experimental
    Sequence CBA

    Bilateral sham stimulation, followed by bilateral active taVNS, then unilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

    Device: Unilateral Active taVNS · Device: Bilateral Sham taVNS

Interventions

  • DeviceUnilateral Active taVNS

    Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.

  • DeviceBilateral Sham taVNS

    Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes.

06

What researchers measure

Primary outcomes

  1. Change in Shimmer (%)

    Shimmer (%) will be measured using Praat software from three sustained /a/ phonations. The stable middle 3-second segment of each recording will be analyzed, and the mean of three measurements will be used. Change will be calculated as post-intervention minus baseline shimmer.

    Time frame: At each of three visits: before intervention and after the 20-minute intervention and 5-minute PRV recording; visits separated by at least 7 days.

  2. Change in Jitter (%)

    Change in cycle-to-cycle fundamental frequency variation, measured using Praat software from three sustained /a/ phonations.

    Time frame: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.

  3. Change in Harmonics-to-Noise Ratio (dB)

    Change in voice harmonic-to-noise ratio, measured using Praat software from three sustained /a/ phonations.

    Time frame: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.

  4. Change in Fundamental Frequency (Hz)

    Change in mean fundamental frequency (F0), measured using Praat software from three sustained /a/ phonations.

    Time frame: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.

  5. Change in Perceived Vocal Effort (mm)

    Change in perceived vocal effort assessed using a 100-mm visual analogue scale (VAS), where higher scores indicate greater perceived vocal effort.

    Time frame: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.

  6. Change in RMSSD (ms)

    Change in the root mean square of successive differences (RMSSD), calculated from 5-minute pulse rate variability recordings using Polar Verity Sense.

    Time frame: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.

  7. Change in SDNN (ms)

    Change in the standard deviation of normal-to-normal pulse intervals (SDNN), calculated from 5-minute pulse rate variability recordings using Polar Verity Sense.

    Time frame: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.

  8. hange in Mean Heart Rate (bpm)

    Change in mean heart rate measured using Polar Verity Sense during 5-minute recordings.

    Time frame: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.

  9. Change in LF/HF Ratio

    Exploratory analysis of the low-frequency to high-frequency power ratio derived from pulse rate variability recordings.

    Time frame: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Choi SH, Choi WS, Han GY. Acoustic voice changes induced by transcutaneous auricular vagus nerve stimulation. Clinical Archives of Communication Disorders. 2025;10(3):143-153. doi:10.21849/cacd.2025.10.3.3.
  • Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009 Nov;41(4):1149-60. doi: 10.3758/BRM.41.4.1149. PubMed 19897823 ↗
  • Yoshida Y, Okayama S, Fujihara D, Taniyama M, Yamada A, Fukui M, Doi N, Takahashi R, Tanabe A, Ogaki S, Hattori S, Iwai A, Nakamura M, Doi N, Saito Y. Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Hemodynamics and Autonomic Function During Exercise Stress Tests in Healthy Volunteers. Circ Rep. 2025 Apr 11;7(5):315-322. doi: 10.1253/circrep.CR-24-0136. eCollection 2025 May 9. PubMed 40352124 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared with external researchers to protect participant confidentiality and privacy. Study findings will be reported in aggregate form in scientific publications.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jan 2027, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Nov 16, 2026
Primary completionEst.
Jan 15, 2027
CompletionEst.
Jan 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937813
Lead sponsor
Sinop University
Responsible party
SEFA HAKTAN HATIK (Assistant Professor, Sinop University) — Principal investigator
First posted
Nov 16, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Jan 15, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Sefa Haktan Hatık Principal Investigator, PhD, MSc, Physiotherapist
Contact
haktanhtk@gmail.com
+90 505 876 1553

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion